Nuvocid (oritavancin) at single or infrequent doses for the treatment of complicated skin and skin structure infections (SIMPLIFI)
Latest Information Update: 02 Sep 2024
At a glance
- Drugs Oritavancin (Primary)
- Indications Skin and soft tissue infections
- Focus Therapeutic Use
- Acronyms SIMPLIFI
- Sponsors Targanta Therapeutics Corporation
- 05 Jun 2017 Characteristics of bacterial isolates data from this study presented at the ASM Microbe 2017
- 30 Oct 2016 Results presented at the IDWeek 2016
- 02 May 2011 Results published in Antimicrobial Agents and Chemotherapy.